Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Deucrictibant
Other

Deucrictibant

Tracked across 1 events · 8 articles · First seen May 29, 2026 · Last active May 29, 2026

Sentiment
70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Tech
Pharvaris Presents Deucrictibant Clinical Data
Pharvaris, a late-stage biopharmaceutical company, announced the acceptance of one oral presentation and seven flash talk/poster presentations at the European Academy of Allergy and Clinical Immunology Annual Congress 2026 in Istanbul, Turkey, from June 12-15,…
Impact: Deucrictibant is the novel oral drug developed by Pharvaris, with clinical data being presented for its use in treating hereditary angioedema and acquired angioedema.
May 29, 2026 · 8 articles
NEWSDESK
Track Deucrictibant live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.